In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur ...